Effects of dapagliflozin on primary and secondary outcomes consistent for those with eGFR <60 and ≥60 mL/min per 1.73 m2
FRIDAY, April 29, 2022 (HealthDay News) — The effects of dapagliflozin are similar for hospitalized patients with COVID-19 with estimated glomerular filtration rate (eGFR) <60 and ≥60 mL/min per 1.73 m2, according to a study published online April 28 in the Clinical Journal of the American Society of Nephrology.
Hiddo J. L. Heerspink, Ph.D., Pharm.D., from the University Medical Center Groningen in the Netherlands, and colleagues conducted a secondary analysis of the Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial, which randomly assigned 1,250 hospitalized patients with COVID-19 and cardiometabolic risk factors to dapagliflozin or placebo. Dual primary outcomes (time to new or worsened organ dysfunction or death, and a hierarchical composite end point of recovery) and key secondary kidney outcomes were assessed among those with baseline eGFR <60 and ≥60 mL/min per 1.73 m2.
The researchers found that across eGFR subgroups, the effect of dapagliflozin versus placebo was consistent on the primary prevention outcome (hazard ratio, 0.80; 95 percent confidence interval, 0.58 to 1.10), primary recovery outcome (win ratio, 1.09; 95 percent confidence interval, 0.97 to 1.22), and the composite kidney outcome (hazard ratio, 0.74; 95 percent confidence interval, 0.50 to 1.07; P for interaction, 0.98, 0.67, and 0.44, respectively). The effects of dapagliflozin on acute kidney injury were also similar for those with eGFR <60 mL/min per 1.73 m2 (hazard ratio, 0.71; 95 percent confidence interval, 0.29 to 1.77) and ≥60 mL/min per 1.73 m2 (hazard ratio, 0.69; 95 percent confidence interval, 0.37 to 1.29). In patients with eGFR <60 and ≥60 mL/min per 1.73 m2, dapagliflozin was well tolerated.
“These new data from DARE-19 reinforce the safety of dapagliflozin in acutely ill patients hospitalized with COVID-19 even in those with reduced kidney function who are at particularly high risk of acute kidney injury,” Heerspink said in a statement.
Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which manufactures dapagliflozin and funded the study.
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML 
Updated Recommendations Address Medications to Prevent Migraine in Adults 
Biomarkers Plus Kidney Donor Profile Index Improve Prediction of Concordant Allograft Outcomes 
2011 to 2021 Saw Heart Failure-Related Hospitalization Rise in CKD 
Short-Term Pretransplant Dialysis Does Not Affect Kidney Transplant Outcomes 
Machine Learning Model IDs Heart Failure With Reduced Ejection Fraction Using Routine Lab Indicators 
Extreme Heat Linked to 33 Clinically Reportable Diagnoses 
Lower Protein Diet May Be Better in Incremental Peritoneal Dialysis 
